affiliation not provided to SSRN
melanoma, targeted therapy, BRAF and MEK inhibitors, Anticoagulation, Direct oral anticoagulants (DOACs), Factor Xa inhibitors, Progression-free survival (PFS), Overall survival (OS), Platelet aggregation inhibition, Venous thromboembolism (VTE), Immunothrombosis